FABP Veterinary Vaccine Composition for Persistent Helminth Immunity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current vaccine compositions for helminths, particularly Fasciola hepatica, lack effective adjuvants that induce potent and persistent immune responses, leading to significant economic losses in livestock and limited efficacy in preventing infections.

Innovation Solution

A veterinary vaccine composition using Fatty Acid Binding Proteins (FABPs) from parasites, specifically Schistosoma mansoni rSm14 protein or Fasciola hepatica homologous proteins, formulated in a water-in-oil emulsion with adjuvants like saponin and Quil-A, to stimulate a homogeneous and long-lasting immune response.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional vaccine compositions are used without effective adjuvants, then the vaccine can be administered, but the immune response is weak and not persistent

Engineering Contradiction:

Improveefficacy of vaccineVSAvoidpersistence of immune response

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent introduces saponin and Quil-A as intermediary adjuvant substances that mediate between the antigen (FABPs) and the host immune system. These adjuvants act as mediators to enhance and prolong the immune response, solving the contradiction between initial vaccine administration and persistent immunity by adding a third component that bridges the gap.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the chemical and immunological parameters of the vaccine composition by incorporating specific adjuvants (saponin, Quil-A) that modify the immune system's response characteristics. This parameter change transforms a weak, transient response into a potent, persistent immune response through altered biochemical interactions.

Inventive Principle:

Principle #35Parameter changes

2Device complexity

If no adjuvants are added to the vaccine, then the formulation is simple, but the immune response is not potent enough

Engineering Contradiction:

Improvevaccine formulation complexityVSAvoidpotency of immune response

Core Design Contradiction:

Device complexityVSReliability

Solution Approach 1:

The patent creates a composite vaccine formulation by combining the antigen (FABPs) with adjuvant materials (saponin, Quil-A). This composite approach integrates multiple functional components that work synergistically to produce a potent immune response while maintaining a relatively simple overall formulation structure.

Inventive Principle:

Principle #40Composite materials

3Adaptability or versatility

If the vaccine uses FABPs from parasites, then it can induce both humoral and cellular immune responses, but the formulation requires specific adjuvants to achieve this

Engineering Contradiction:

Improvetype of immune responseVSAvoidadjuvant formulation requirements

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent achieves multi-functionality by selecting adjuvants (saponin, Quil-A) that can simultaneously enhance both humoral and cellular immune responses. These universal adjuvants perform multiple functions: they stimulate antibody production, enhance T-cell responses, and prolong immunity, thereby supporting the versatile immune response induction capability of the FABP antigen.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20250319170A1Veterinary Vaccine Composition Against Parasitic Worms, Method for Treating and Preventing Infection by Parasitic Worms, and Use

Publication Date: 2025.10.16 FABP BIOTECH DESENVOLVIMENTO EM BIOTECNOLOGIA LTDA

AI summary

The present invention relates to a veterinary vaccine composition based on fatty-acid-binding proteins (FABP) from parasites. Specifically, the invention discloses a veterinary vaccine composition based on the Schistosoma mansoni protein (rSm14) or homologous proteins of Fasciola hepatica (FhFABPs) that provide a homogeneous, long-term immune response against parasitic worms. The invention is also intended to provide a method for treating and preventing infection caused by parasitic worms, in particular Fasciola hepatica, and also the use of these proteins in a vaccine composition against parasitic worms.